NASDAQ:EYPT

Eyepoint Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy EYPT

*Your capital is at risk

$14.28

-0.440 (-2.99%)

At Close: Jul 13, 2026

EyePoint Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 28.62. In total, the insiders bought 2.39M and sold 693.67K EYPT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	28.62
● Buy	2.39M shares
● Sell	693.67K shares
68% Buy Activity Weak Negative Correlation
Sell Signal Low Confidence Jun 30, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 28.62. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 30, 2026 Buy	Common Stock M-Exempt	Ribeiro Ramiro Chief Medical Officer	Officer	2 438 Value: $20.1K
Jun 30, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Ribeiro Ramiro Chief Medical Officer	Officer	2 438 Value: $20.1K
Jun 30, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Ribeiro Ramiro Chief Medical Officer	Officer	2 437 Value: $20.1K
Jun 30, 2026 Sell	Common Stock S-Sale	Ribeiro Ramiro Chief Medical Officer	Officer	2 437 Value: $36.6K
Jun 30, 2026 Buy	Common Stock M-Exempt	Ribeiro Ramiro Chief Medical Officer	Officer	2 437 Value: $20.1K
Jun 30, 2026 Sell	Common Stock S-Sale	Ribeiro Ramiro Chief Medical Officer	Officer	2 438 Value: $36.6K
May 25, 2026 Buy	Restricted Stock Units M-Exempt	Elston George Chief Financial Officer	C-Suite Officer	7 500 Value: $107.1K
May 25, 2026 Sell	Common Stock F-InKind	Elston George Chief Financial Officer	C-Suite Officer	3 627 Value: $46.9K
May 25, 2026 Buy	Common Stock M-Exempt	Elston George Chief Financial Officer	C-Suite Officer	7 500 Value: $107.1K
Apr 17, 2026 Sell	Common Stock S-Sale	Ribeiro Ramiro Chief Medical Officer	Officer	2 437 Value: $36.6K
Apr 17, 2026 Buy	Common Stock M-Exempt	Ribeiro Ramiro Chief Medical Officer	Officer	2 437 Value: $20.1K
Apr 17, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Ribeiro Ramiro Chief Medical Officer	Officer	2 437 Value: $20.1K
Mar 23, 2026 Sell	Common Stock J-Other	Duker Jay S. President And CEO	CEO / President	76 766 Value: $1.01M
Mar 23, 2026 Buy	Stock Option (Right to Buy) J-Other	Duker Jay S. President And CEO	CEO / President	52 500 Value: $689.3K
Mar 23, 2026 Sell	Stock Option (Right to Buy) J-Other	Duker Jay S. President And CEO	CEO / President	97 500 Value: $1.99M
Mar 23, 2026 Buy	Stock Option (Right to Buy) J-Other	Duker Jay S. President And CEO	CEO / President	97 500 Value: $1.99M
Mar 23, 2026 Buy	Common Stock J-Other	Duker Jay S. President And CEO	CEO / President	76 766 Value: $1.01M
Mar 23, 2026 Sell	Stock Option (Right to Buy) J-Other	Duker Jay S. President And CEO	CEO / President	52 500 Value: $689.3K
Mar 16, 2026 Buy	Common Stock P-Purchase	Duker Jay S. President And CEO	CEO / President	1 500 Value: $19.7K
Mar 04, 2026 Sell	Common Stock S-Sale	Ribeiro Ramiro Chief Medical Officer	Officer	2 438 Value: $43.6K
Mar 04, 2026 Buy	Common Stock M-Exempt	Ribeiro Ramiro Chief Medical Officer	Officer	2 438 Value: $20.1K
Mar 04, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Ribeiro Ramiro Chief Medical Officer	Officer	2 438 Value: $20.1K
Mar 02, 2026 Sell	Common Stock G-Gift	Elston George Chief Financial Officer	C-Suite Officer	5 000 Value: $0
Mar 02, 2026 Buy	Common Stock G-Gift	Elston George Chief Financial Officer	C-Suite Officer	5 000 Value: $91.7K
Feb 17, 2026 Buy	Common Stock M-Exempt	Ribeiro Ramiro Chief Medical Officer	Officer	2 437 Value: $20.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT EYEPOINT PHARMACEUTICALS INC.

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting...

Read Full Profile Here